
Emcure Pharmaceuticals IPO
- Issue price
- ₹1,008
- Listing price
- ₹1,325.05
- +31.45%
- Current price
- ₹2,361.7
- +134.30%
- Subscribed
- 68.41x
- Issue size
- ₹1,952.03 Cr
- Listed on
- 10 Jul 2024
IPO timeline
- Opens3 JulWed
- Closes5 JulFri
- Allotment8 JulMon
- Refunds9 JulTue
- Demat credit9 JulTue
- Listing10 JulWed
Issue details
- Price band
- ₹960 – ₹1,008 per share
- Issue size
- ₹1,952.03 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹10 per share
- Lot size
- 14 shares
- Minimum investment
- ₹14,112
- Listing on
- BSE, NSE
- Exchange code
- EMCURE · 544210
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,112 |
| Retail (Max) | 14 | 196 | ₹1,97,568 |
| S-HNI (Min) | 15 | 210 | ₹2,11,680 |
| B-HNI (Min) | 71 | 994 | ₹10,01,952 |
Reservation
- QIB
- 96,33,084 shares (50.00% of the Offer)
- NII
- 28,89,926 shares (15.00% of the Offer)
- Retail
- 67,43,160 shares (35.00% of the Offer)
- Employee
- 1,08,900 shares (0.56% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 8 Jul 2024
- Refunds initiated
- 9 Jul 2024
- Shares credited to demat
- 9 Jul 2024
- Listing
- 10 Jul 2024
Grey market premium (GMP)
- Current GMP
- ₹360
- +36.00%
- Estimated listing price
- ₹1,368
- Issue price ₹1,008
- Highest
- ₹365
- 8 Jul
- Lowest
- ₹250
- 29 Jun
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 9 Jul 2024 | ₹360 | +36.00% | ₹1,368 |
| 8 Jul 2024 | ₹365 | +36.00% | ₹1,373 |
| 6 Jul 2024 | ₹355 | +35.00% | ₹1,363 |
| 5 Jul 2024 | ₹320 | +32.00% | ₹1,328 |
| 4 Jul 2024 | ₹310 | +31.00% | ₹1,318 |
| 3 Jul 2024 | ₹282 | +28.00% | ₹1,290 |
| 2 Jul 2024 | ₹275 | +27.00% | ₹1,283 |
| 1 Jul 2024 | ₹260 | +26.00% | ₹1,268 |
| 29 Jun 2024 | ₹250 | +25.00% | ₹1,258 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB191.24x
- NII (HNI)49.32x
- Retail7.36x
- Employee8.81x
Financials
- P/E Ratio
- 36.07
- EPS (₹)
- 27.95
- RoE
- 16.90%
- RoCE
- 19.37%
- RoNW
- 16.87%
- PAT Margin
- 7.86%
- Debt / Equity
- 0.67
- NAV (₹)
- 163.22
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Total Income | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| NET Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals This IPO | ₹1,952.03 Cr | 36.07 | 16.87% | 7.86% | 68.41x | +31.45% |
| Urban Company Mainboard · listed 17 Sep 2025 | ₹1,900 Cr | 61.68 | 13.35% | — | 108.96x | +57.52% |
| Allied Blenders & Distillers Mainboard · listed 2 Jul 2024 | ₹1,500 Cr | 1393.87 | 1.03% | 0.17% | 24.77x | +13.88% |
| Dr. Agarwal's Health Care Mainboard · listed 4 Feb 2025 | ₹3,027.26 Cr | 160.48 | 6.21% | 6.90% | 1.49x | 0.00% |
| DOMS Industries Mainboard · listed 20 Dec 2023 | ₹1,200 Cr | 32.43 | 28.39% | 2.51% | 98.51x | +77.22% |
| DAM Capital Advisors Mainboard · listed 27 Dec 2024 | ₹840.25 Cr | 28.37 | 44.98% | 38.75% | 81.88x | +38.87% |
| Anand Rathi Share & Stock Brokers Mainboard · listed 30 Sep 2025 | ₹745 Cr | 25.06 | 23.12% | 12.23% | 21.8x | +4.35% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Emcure Pharmaceuticals plans to use the money raised, as stated in the offer document.
- Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company₹800 Cr
- General corporate purposes₹41.14 Cr
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited was incorporated as Emcure Pharmaceuticals Private Limited on 16 April 1981. It is an Indian pharmaceutical company that develops, makes and markets a broad range of products across major therapy areas. It is research driven, with a portfolio of orals, injectables and biotherapeutics that reaches over 70 countries, with a strong presence in India, Europe and Canada. In India it works across acute and chronic therapy areas, including gynaecology, cardiovascular, vitamins and minerals and HIV antivirals. Its promoters include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta. The IPO was Rs 1,952.03 crore, with Rs 800.58 crore of fresh issue and Rs 1,151.45 crore of offer for sale, mostly by BC Investments IV, with promoters and promoter group members also selling. Rs 800.00 crore was planned for repaying borrowings.
Strengths
- Total income rose from Rs 5,918.86 crore in FY2022 to Rs 6,715.24 crore in FY2024.
- Rs 800.00 crore of the fresh issue was planned for repaying debt.
- It sells in over 70 countries, with a strong presence in India, Europe and Canada.
- Net worth grew from Rs 1,987.55 crore on 31 March 2022 to Rs 2,952.28 crore on 31 March 2024.
- The source puts return on net worth at 16.87%.
Risks
- Profit after tax fell from Rs 702.56 crore in FY2022 to Rs 527.58 crore in FY2024.
- The pre-issue P/E was 34.55 at the upper band of Rs 1,008, based on EPS of Rs 29.17.
- Total borrowing was Rs 2,091.94 crore on 31 March 2024.
- Rs 1,151.45 crore of the issue was offer for sale, and overseas markets add regulatory and currency risk.
- Promoters and the promoter group held 83.21% before the issue and about 78.24% after it, as per the RHP share counts.
Promoters and shareholding
Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta
- Promoter holding, pre-issue
- 83.21%
- Promoter holding, post-issue
- 78.24%
Anchor investors
Registrar, lead managers and documents
Lead managers
Documents
Emcure Pharmaceuticals IPO: common questions
1.When does the Emcure Pharmaceuticals IPO open and close?
The Emcure Pharmaceuticals IPO opens on 3 Jul 2024 and closes on 5 Jul 2024.
2.What is the price band of the Emcure Pharmaceuticals IPO?
The price band is ₹960 – ₹1,008 per share, with a lot size of 14 shares and a minimum investment of ₹14,112.
3.What is the size of the Emcure Pharmaceuticals IPO?
The issue size is ₹1,952.03 Cr (Fresh capital cum OFS).
4.What is the GMP of the Emcure Pharmaceuticals IPO?
The last reported grey market premium is ₹360 per share as of 09 Jul 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Emcure Pharmaceuticals IPO allotment?
The basis of allotment is expected on 8 Jul 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Emcure Pharmaceuticals IPO list?
The shares listed on 10 Jul 2024 on BSE, NSE.
7.Who is the lead manager of the Emcure Pharmaceuticals IPO?
The book running lead managers are Axis Capital, Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, JP Morgan India Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Emcure Pharmaceuticals IPO be used for?
As stated in the offer document, the proceeds are for: Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company; General corporate purposes.
9.How can my company launch an IPO like Emcure Pharmaceuticals?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393